China Pharma Holdings Files 2024 Proxy Statement

TL;DR

China Pharma Holdings filed its 2024 proxy statement, shareholders vote soon.

AI Summary

China Pharma Holdings, Inc. filed its Definitive Proxy Statement (DEF 14A) on November 12, 2024, for the fiscal year ending December 31, 2024. The filing concerns the company's annual meeting and related corporate governance matters. The company, previously known as TS Electronics Inc. and Softstone Inc., is incorporated in Delaware and operates in the pharmaceutical preparations industry.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance, executive compensation, and voting matters, enabling informed participation in the annual meeting.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing for annual shareholder meeting matters, not indicating new financial risks.

Key Numbers

• 20241222 — Fiscal Year End (The company's financial reporting period concludes on this date.)
• 20241112 — Filing Date (The date the Definitive Proxy Statement was submitted to the SEC.)

Key Players & Entities

• CHINA PHARMA HOLDINGS, INC. (company) — Registrant
• TS ELECTRONICS INC (company) — Former company name
• SOFTSTONE INC (company) — Former company name
• 20241112 (date) — Filing date
• 20241222 (date) — Fiscal year end

FAQ

Key Financial Figures

• $0.001 — every holder of common stock, par value $0.001 per share, of the Company (the “C
• $100,000 — icer received compensation in excess of $100,000 during the fiscal year ended December 3
• $241,600 — 023, from our U.S. holding company, was $241,600. Payments upon Termination or Change-i
• $6,202 — ompensation of RMB40,000 (approximately $6,202), payable quarterly and Mr. Bennett is
• $16,000 — itled to receive annual compensation of $16,000, payable quarterly, and a warrant to pu
• $0.55 — of common stock at an exercise price of $0.55 per share. As of the date of this Proxy
• $120,000 — cipant and the amount involved exceeded $120,000; none of our executive officers serve
• $132,000 — lings or engagements were approximately $132,000 and $123,000 for the fiscal year ended
• $123,000 — gements were approximately $132,000 and $123,000 for the fiscal year ended December 31,

Filing Documents

• ea0220766-def14a_chinapharma.htm (DEF 14A) — 228KB
• proxy_001.jpg (GRAPHIC) — 756KB
• proxy_002.jpg (GRAPHIC) — 167KB
• proxy_003.jpg (GRAPHIC) — 361KB
• proxy_004.jpg (GRAPHIC) — 543KB
• 0001213900-24-096780.txt ( ) — 2745KB

SECURITY OWNERSHIP OF CERTAIN

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information as of November 1, 2024, with respect to the beneficial ownership of our common stock, the sole outstanding class of our voting securities, by (i) any person or group owning more than 5% of each class of voting securities, (ii) each director, (iii) each executive officer and (iv) all executive officers and directors as a group. As of November 1, 2024, an aggregate of 18,556,499 shares of our common stock were outstanding. Name and Address of Beneficial Owners(1)(2) Amount and Nature of Beneficial Percent of Class(3) Directors and Executive Officers Zhilin Li President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board 3,027,613 16.32 % Heung Mei Tsui Director 186,254 1.00 % Yingwen Zhang Director - - Gene Michael Bennett (4) Director - - Baowen Dong Director - - All directors and executive officers as a group (5 persons) 3,213,867 17.32 % Beneficial stockholders with 5% or more ownership Zhilin Li 3,026,613 16.31 % Kui Lai 1,000,000 5.39 % Jianying Cai 1,000,000 5.39 % Lihua Li 1,000,000 5.39 % Tao Liu 3,000,000 16.17 % * Represents less than 1%. (1) Pursuant to Rule 13d-3 under the Exchange Act, a person has beneficial ownership of any securities as to which such person, directly or indirectly, through any contract, arrangement, undertaking, relationship or otherwise has or shares voting power and/or investment power or as to which such person has the right to acquire such voting and/or investment power within 60 days. (2) Unless otherwise stated, each beneficial owner has sole power to vote and dispose of the shares and the address of such person is c/o China Pharma Holdings, Inc., 2nd Floor, No. 17 Jinpan Road, Haikou, Hainan Province, People’s Republic of China 570216. (3) In determining the percentage of common stock owned by

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION Summary of Executive Compensation The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive officer and principal financial officer during the last two fiscal years in all capacities to our Company and our subsidiaries. No other executive officer received compensation in excess of $100,000 during the fiscal year ended December 31, 2023. SUMMARY COMPENSATION TABLE Stock Option Non-Equity Incentive Plan Nonqualified Deferred Compensation All Other Year Salary Bonus Awards Awards Compensation Earnings Compensation Total Name and principal position Ended ($) ($) ($) ($) ($) ($) ($) ($) Zhilin Li 2023 225,600 16,000 241,600 Chairman, Chief 2022 225,600 - - - - - 16,000 241,600 Executive Officer President and interim Chief Financial Officer Employment Agreements Zhilin Li . Hainan Helpson Medical & Biotechnology Co., Ltd., our wholly-owned subsidiary and operating entity in the PRC (“Helpson”), entered into an employment agreement with Ms. Zhilin Li, our Chairman of the Board and Chief Executive Officer. Upon the expiration of the original agreement, Helpson renewed the agreement with Ms. Li on the same terms as the original agreement. The new employment agreement will expire on June 30, 2025. Pursuant to the terms of the new employment agreement, Ms. Li agreed to continue to serve as Helpson’s Chief Executive Officer for a term of five years at an annual salary of RMB800,000. Helpson may adjust Ms. Li’s compensation based upon her production and operating achievement and her technical ability and working performance. Ms. Li’s total annual cash compensation for the fiscal year ended December 31, 2023, from our U.S. holding company, was $241,600. Payments upon Termination or Change-in-Control PRC Law. Under the applicable laws of the PRC, we must pay severance to all employe

View Full Filing

View this DEF 14A filing on SEC EDGAR